• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Lenalidomide in multiple myeloma: current role and future directions.
【24h】

Lenalidomide in multiple myeloma: current role and future directions.

机译：半三营胺在多发性骨髓瘤中：当前的作用和未来方向。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: Lenalidomide and other new agents are improving survival of multiple myeloma patients. This review describes current data on lenalidomide in myeloma and how the unique properties of lenalidomide may lend its use in new settings, such as maintenance and preventive therapy. AREAS COVERED IN THIS REVIEW: This review covers the activity of lenalidomide in multiple myeloma, efficacy in both newly diagnosed and relapsed/refractory patients, how to manage effectively common adverse events observed with lenalidomide, and its potential use in new settings based on clinical trials published up to 2009. WHAT THE READER WILL GAIN: This review describes the mechanism of action of lenalidomide in myeloma which provides the basis for its clinical use in newly diagnosed, relapsed/refractory, and high-risk smoldering myeloma in combination with other agents. Strategies to reduce or effectively manage myelosuppression and thromboembolic events, the main adverse events associated with lenalidomide plus dexamethasone therapy, are also described. TAKE HOME MESSAGE: Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents.
机译：该领域的重要性：Lenalidomide和其他新药正在改善多个骨髓瘤患者的存活。该综述描述了骨髓瘤中Lenalidomide的当前数据以及Lenalidomide的独特性质可以借给新的设置，例如维护和预防治疗。本报告所涵盖的地区：本报告涵盖了多种骨髓瘤的活性，在新诊断和复发/难治患者中，如何管理有效地用Lenalidomide观察到的常见不良事件，以及其在基于临床试验的新环境中的潜在用途最多可发布2009年。读者将获得哪些内容：本综述描述了Lenalidomide在骨髓瘤中的作用机制，为其在新诊断，复发/难治性和高风险中的临床用途提供了与其他药剂的高风险浓度的基础。还描述了减少或有效地管理肌球蛋白抑制和血栓栓塞事件的策略，其主要不良事件与番丽比亚二世物加上地塞米松治疗相关。带回家消息：Lenalidomide是一种口服免疫调节药，在治疗多发性骨髓瘤方面具有高度有效，具有有利的安全性曲线，现在被评为维护治疗，预防性治疗和与其他新试剂的结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号